The effect of gaffetuzumab in the treatment of lymphoma

Glofitumab is a novel bispecific antibody designed to treat patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL; non-Hodgkin lymphoma) and large B-cell lymphoma (LBCL) caused by follicular lymphoma. As a CD20-directed CD3 T cell engager, gaffetuzumab significantly enhances the immune system's recognition and attack of tumor cells through a unique mechanism of action. It is an innovative and potential therapy.

The principle of action of Gerfituzumab is that through its bispecific structure, it targets two antigens, CD20 and CD3 respectively. CD20 is an important antigen on the surface of B cells and is widely present in a variety of B cell tumor cells, while CD3 is an important receptor on the surface of T cells. One end of Gefituzumab binds to the CD20 antigen and the other end binds to the CD3 receptor. By "connecting" T cells and tumor cells, it activates the killing effect of T cells on tumor cells. This precise targeting not only enhances the ability of T cells to recognize tumor cells, but also effectively mobilizes other parts of the patient's immune system, such as natural killer cells (NK cells), to further improve the anti-tumor effect.

Graftuzumab has shown significant efficacy in the treatment of patients with relapsed or refractory DLBCL and LBCL. Most patients still face the problem of disease recurrence or drug resistance after multiple chemotherapy treatments, and gaffetuzumab provides a new treatment option for these patients. Multiple clinical trials have shown that gaffetuzumab can effectively control tumor growth, delay disease progression, and significantly improve patients' progression-free survival (PFS). Especially for those patients who have received two or more systemic therapies, gaffetuzumab showed a high response rate and good tolerability.

Reference materials:https://www.drugs.com/glofitamab.html